(PHH) was upgraded at Compass Point to buy from neutral. $26 price target. Company could boost earnings by paying debt early and may be a takeover candidate, Compass Point said.
(POR) was upgraded at Goldman Sachs to buy from neutral. Company has an attractive valuation and can deliver strong earnings growth, Goldman Sachs said.
(PVH - Get Report) was upgraded at Piper Jaffray to overweight from neutral. $121 price target. Visibility catalysts are improving, Piper Jaffray said.
(PX) was downgraded at Citigroup to neutral. Slower growth in China and Brazil and slowing backlog, said Citigroup.
was downgraded at Pacific Crest to underperform. Limited growth prospects and lower earnings projections, Pacific Crest said. Recent settlements and negative rulings suggest weakening patent value, Pacific Crest also said.
was upgraded at Citigroup to buy from sell, as rate expectations shift and earnings normalize, said Citigroup. Price target goes to $24.
was initiated with a buy rating at UBS. $215 price target. Best-in-class play on pro paint volume increases, UBS said.
T. Rowe Price
was upgraded at Citigroup to buy as U.S. retail cash flows back into domestic equities, said Citigroup. Price target goes to $82.
was downgraded at Citigroup to neutral. Reflects the impact of declines in mining capex on the company, said Citigroup. Price target goes to $73.
was downgraded to sell at TheStreet Ratings.
was downgraded at Cantor Fitzgerald to hold from buy. Valuation call, based on a $49 price target, Cantor said.
was upgraded at Cowen to outperform from market perform. $112 price target Estimates were also boosted, given higher expected ethylene margins, Cowen said.
STOCK COMMENTS/EPS CHANGES
estimates, price target were reduced at Jefferies. Shares are now seen reaching $405. Estimates were also cut, given lower expected iPhone sales, Jefferies said. Hold rating.
price target and estimates were raised at BMO Capital Markets. Shares are now seen reaching $450. Estimates were also increased due to the companies near-term gross margin growth, BMO Capital Markets said.
Bed Bath & Beyond
numbers were raised at UBS. Earnings estimates were increased given increased visibility to a recovery in home furnishings demand, said UBS. Price target goes to $74.
numbers were cut at UBS. Earnings estimates were reduced given sell-through concerns, said UBS. Price target is $13.
estimates, price target were increased at Bank of America/Merrill Lynch. Estimates were boosted through 2015. Just conducted a bullish dealer survey, BofA/Merrill said. Buy rating and new $50 price target.
estimates, price target were increased at J.P. Morgan through 2014. Search pricing potential is increasing, J.P. Morgan said. Overweight rating and new $1,025 price target.
price target was raised at Citigroup to $96. The Ventures equity stake was marked to market, said Citigroup. Estimates were also adjusted.
price target and estimates were reduced at BMO Capital Markets. Estimates were reduced on increased competition in the SGLT2 drug market, said BMO Capital Markets. Price target was decreased to $52.
estimates, price target were cut at Bank of America/Merrill Lynch. Shares are now seen reaching $160. Estimates were also reduced, given currency headwinds and the disruption in Brazil. Buy rating.
>To submit a news tip, email:
and become a fan on